80321-69-3
80321-69-3 结构式
基本信息
七叶胆苷XVI
七叶胆苷XVⅡ
七叶胆苷XVII
绞股蓝皂甙XVII
绞股蓝皂苷XVII
七叶胆皂苷XVII
七叶胆苷XVII对照品,
七叶胆苷XVII(标准品)
七叶胆苷XVII(绞股蓝皂苷XVII)
Gynosaponin S
Gypenoside ⅩⅦ
GYPENOSIDE-XVII
Gypenoside XVII (Gynosaponin S)
3β-(β-D-Glucopyranosyloxy)-12β-hydroxy-5α-dammar-24-en-20-yl 6-O-β-D-glucopyranosyl-β-D-glucopyranoside
β-D-Glucopyranoside, (3β,12β)-3-(β-D-glucopyranosyloxy)-12-hydroxydammar-24-en-20-yl 6-O-β-D-glucopyranosyl-
(3beta,12beta)-3-(beta-D-Glucopyranosyloxy)-12-hydroxydammar-24-en-20-yl 6-O-beta-D-glucopyranosyl-beta-D-glucopyranoside
物理化学性质
应用领域
药理药效:绞股蓝总皂甙具有人参皂甙的适应原作用，其药理作用大致可分为如下方面:1、消炎，抗肠、胃溃疡和肿疡。2、防癌抗癌。3、活化人体正常细胞（起增强体力、活力、耐力、恢复疲劳和延长寿命的作用）。4、镇静和宁神。5、调节类脂代谢。
常见问题列表
|
Human Endogenous Metabolite
|
The ability of Gypenoside XVII (GP-17) to prevent Ox-LDL-induced cytotoxicity is detected by cell viability assays. Gypenoside XVII does not demonstrate any cytotoxicity in HUVECs. Gypenoside XVII can protect HUVECs against Ox-LDL-induced apoptosis. Gypenoside XVII dose-dependently mitigates the toxic effect of Ox-LDL on HUVEC viability. The viability of HUVECs is significantly higher than that of other groups at 50 μg/mL Gypenoside XVII .
Body weights are measured as physical measures of hormone bioactivity. Mean body weights are significantly higher in every group compared to that of the control, but there is no significant difference in body weight between the different treatments during the 10-week feeding. The mouse plasma lipid levels are also measured at the end of 10 weeks of a high-fat diet. Circulating levels of total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) are significantly increased in the treated groups of ApoE -/- mice compared with those of the C57BL/6J control group; Gypenoside XVII (GP-17) and Probucol treatment substantially decreases both of these parameters relative to those of the ApoE -/- model group.